Nasdaq:US$42.05 (+1.07) | HKEX:HK$70.60 (-7.00) | AIM:£5.95 (+0.03)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Presentations
Recent News
Announcement & Press Releases
Presentations & Publications
Mailing List Sign-up
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Terms of Reference & Policies
Careers
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Presentations
Recent News
Announcement & Press Releases
Presentations & Publications
Mailing List Sign-up
Shareholder Information
Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Terms of Reference & Policies
Careers
News & Presentations
Chi-Med
News & Presentations
| Presentations
Previous Article
|
Next Article
Presentations
,
Scientific Publications
| 1 Jun 2012
ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors
1 items
View Poster (JPG)